Skip to main content
Erschienen in: Annals of Nuclear Medicine 5/2018

20.02.2018 | Short Communication

FDG-PET/CT at the end of immuno-chemotherapy in follicular lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET)

verfasst von: Salvatore Annunziata, Annarosa Cuccaro, Maria Chiara Tisi, Stefan Hohaus, Vittoria Rufini

Erschienen in: Annals of Nuclear Medicine | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

Aim

To retrospectively investigate the prognostic role of the ratio between target lesion and liver SUVmax (rPET) in patients with follicular lymphoma (FL) submitted to FDG-PET/CT at the end of immuno-chemotherapy (PI-PET), and to compare rPET with International Harmonization Project criteria (IHP), Deauville Score (5p-DS) and FL International Prognostic Index at diagnosis (FLIPI).

Methods

Eighty-nine patients with FL undergoing PI-PET were evaluated. The receiver operating characteristic (ROC) approach was applied to identify the optimal cut-point of rPET with respect to 5-years progression free survival (PFS). The prognostic significance of rPET was compared with IHP, DS and FLIPI. Positive predictive value (PPV) and negative predictive value (NPV) were calculated using the presence of adverse events as gold standard.

Results

The ROC analysis for rPET as predictor of progression showed an optimal rPET cut-point of 0.98. Patients with positive values of IHP, DS and rPET had a PFS of 50, 30 and 31%. PPV were of 56, 80 and 80%, NPV of 83, 86 and 88%, respectively. DS and rPET differed only in two patients. FLIPI was not predictive of progression and relapse.

Conclusions

rPET is a prognostic factor in patients with FL submitted to PI-PET. Although it has a similar prognostic power as DS, it can have methodological advantages over visual analysis. PI-PET with different evaluation systems has a stronger prognostic power than FLIPI at diagnosis, so it could be useful to identify patients with FL at risk for early relapse after immuno-chemotherapy.
Literatur
1.
Zurück zum Zitat Wong-Sefidan I, Byrtek M, Zhou X, et al. [18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice. Leuk Lymphoma. 2017;58(4):809–15.CrossRefPubMed Wong-Sefidan I, Byrtek M, Zhou X, et al. [18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice. Leuk Lymphoma. 2017;58(4):809–15.CrossRefPubMed
2.
Zurück zum Zitat Kostakoglu L, Goy A, Martinelli G, et al. FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study. Leuk Lymphoma. 2017;58(2):372–81.CrossRefPubMed Kostakoglu L, Goy A, Martinelli G, et al. FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study. Leuk Lymphoma. 2017;58(2):372–81.CrossRefPubMed
3.
Zurück zum Zitat Dupuis J, Berriolo-Riedinger A, Julian A, et al. Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d’Etudes des Lymphomes de l’Adulte and GOELAMS. J Clin Oncol. 2012;30(35):4317–22.CrossRefPubMed Dupuis J, Berriolo-Riedinger A, Julian A, et al. Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d’Etudes des Lymphomes de l’Adulte and GOELAMS. J Clin Oncol. 2012;30(35):4317–22.CrossRefPubMed
4.
Zurück zum Zitat Lu Z, Lin M, Downe P, et al. The prognostic value of mid- and post-treatment [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET) in indolent follicular lymphoma. Ann Nucl Med. 2014;28(8):805–11.CrossRefPubMed Lu Z, Lin M, Downe P, et al. The prognostic value of mid- and post-treatment [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET) in indolent follicular lymphoma. Ann Nucl Med. 2014;28(8):805–11.CrossRefPubMed
5.
Zurück zum Zitat Luminari S, Biasoli I, Versari A, et al. The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL). Ann Oncol. 2014;25(2):442–7.CrossRefPubMed Luminari S, Biasoli I, Versari A, et al. The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL). Ann Oncol. 2014;25(2):442–7.CrossRefPubMed
6.
Zurück zum Zitat Trotman J, Luminari S, Boussetta S, et al. Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies. Lancet Haematol. 2014;1(1):e17–27.CrossRefPubMed Trotman J, Luminari S, Boussetta S, et al. Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies. Lancet Haematol. 2014;1(1):e17–27.CrossRefPubMed
7.
Zurück zum Zitat Tychyj-Pinel C, Ricard F, Fulham M, et al. PET/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study. Eur J Nucl Med Mol Imaging. 2014;41(3):408–15.CrossRefPubMed Tychyj-Pinel C, Ricard F, Fulham M, et al. PET/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study. Eur J Nucl Med Mol Imaging. 2014;41(3):408–15.CrossRefPubMed
8.
Zurück zum Zitat Adams HJ, Nievelstein RA, Kwee TC. Prognostic value of interim and end-of-treatment FDG-PET in follicular lymphoma: a systematic review. Ann Hematol. 2016;95(1):11–18.CrossRefPubMed Adams HJ, Nievelstein RA, Kwee TC. Prognostic value of interim and end-of-treatment FDG-PET in follicular lymphoma: a systematic review. Ann Hematol. 2016;95(1):11–18.CrossRefPubMed
9.
Zurück zum Zitat Adams HJ, Kwee TC. No convincing evidence to support postinduction FDG-PET in follicular lymphoma. Ann Hematol. 2016;95(12):2085–6.CrossRefPubMed Adams HJ, Kwee TC. No convincing evidence to support postinduction FDG-PET in follicular lymphoma. Ann Hematol. 2016;95(12):2085–6.CrossRefPubMed
10.
Zurück zum Zitat Annunziata S, Cuccaro A, Calcagni ML, et al. Interim FDG-PET/CT in Hodgkin lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET). Ann Nucl Med. 2016;30(8):588–92.CrossRefPubMed Annunziata S, Cuccaro A, Calcagni ML, et al. Interim FDG-PET/CT in Hodgkin lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET). Ann Nucl Med. 2016;30(8):588–92.CrossRefPubMed
11.
Zurück zum Zitat Hasenclever D, Kurch L, Mauz-Körholz C, et al. qPET—a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:1301–8.CrossRefPubMed Hasenclever D, Kurch L, Mauz-Körholz C, et al. qPET—a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:1301–8.CrossRefPubMed
12.
Zurück zum Zitat Provencio Pulla M, Alfaro Lizaso J, de la Cruz Merino L, et al. SEOM clinical guidelines for the treatment of follicular non-Hodgkin’s lymphoma. Clin Transl Oncol. 2015;17(12):1014–9.CrossRefPubMedPubMedCentral Provencio Pulla M, Alfaro Lizaso J, de la Cruz Merino L, et al. SEOM clinical guidelines for the treatment of follicular non-Hodgkin’s lymphoma. Clin Transl Oncol. 2015;17(12):1014–9.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Chiaravalloti A, Danieli R, Abbatiello P, et al. Factors affecting intrapatient liver and mediastinal blood pool 18F-FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:1123–32.PubMed Chiaravalloti A, Danieli R, Abbatiello P, et al. Factors affecting intrapatient liver and mediastinal blood pool 18F-FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:1123–32.PubMed
14.
Zurück zum Zitat Laffon E, Marthan R. Interim FDG PET scans in lymphoma: SUV measurement error may impair qPET methodology. Eur J Nucl Med Mol Imaging. 2014;41:2154.CrossRefPubMed Laffon E, Marthan R. Interim FDG PET scans in lymphoma: SUV measurement error may impair qPET methodology. Eur J Nucl Med Mol Imaging. 2014;41:2154.CrossRefPubMed
15.
Zurück zum Zitat Hasenclever D, Kurch L, Kluge R. Sources of variability in FDG PET imaging and the qPET value: reply to Laffon and Marthan. Eur J Nucl Med Mol Imaging. 2014;41:2155–7.CrossRefPubMed Hasenclever D, Kurch L, Kluge R. Sources of variability in FDG PET imaging and the qPET value: reply to Laffon and Marthan. Eur J Nucl Med Mol Imaging. 2014;41:2155–7.CrossRefPubMed
16.
Zurück zum Zitat Laffon E, de Clermont H, Lamare F, et al. Liver SUV versus stage in Hodgkin’s lymphoma: the total amount of uptake may play a role in the inverse relationship. Eur J Nucl Med Mol Imaging. 2015;42:164–5.CrossRefPubMed Laffon E, de Clermont H, Lamare F, et al. Liver SUV versus stage in Hodgkin’s lymphoma: the total amount of uptake may play a role in the inverse relationship. Eur J Nucl Med Mol Imaging. 2015;42:164–5.CrossRefPubMed
17.
Zurück zum Zitat Chiaravalloti A, Schillaci O. Reply to comments by Laffon et al. Liver SUV versus stage in Hodgkin’s lymphoma: the total amount of uptake may play a role in the inverse relationship. Eur J Nucl Med Mol Imaging. 2015;42:166.CrossRefPubMed Chiaravalloti A, Schillaci O. Reply to comments by Laffon et al. Liver SUV versus stage in Hodgkin’s lymphoma: the total amount of uptake may play a role in the inverse relationship. Eur J Nucl Med Mol Imaging. 2015;42:166.CrossRefPubMed
18.
Zurück zum Zitat Adams MC, Turkington TG, Wilson JM, et al. A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol. 2010;195:310–20.CrossRefPubMed Adams MC, Turkington TG, Wilson JM, et al. A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol. 2010;195:310–20.CrossRefPubMed
Metadaten
Titel
FDG-PET/CT at the end of immuno-chemotherapy in follicular lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET)
verfasst von
Salvatore Annunziata
Annarosa Cuccaro
Maria Chiara Tisi
Stefan Hohaus
Vittoria Rufini
Publikationsdatum
20.02.2018
Verlag
Springer Japan
Erschienen in
Annals of Nuclear Medicine / Ausgabe 5/2018
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-018-1243-2

Weitere Artikel der Ausgabe 5/2018

Annals of Nuclear Medicine 5/2018 Zur Ausgabe